Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CADL vs EDIT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CADL Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 7–3 Matrix Metrics)

CADL Overall Winner 6-Pillar Tally: CADL 3 – 3 EDIT Matrix Metrics: CADL 7 – 3 EDIT

As of Nov 16, 2026, Candel Therapeutics, Inc. (CADL) is the stronger overall head-to-head candidate over Editas Medicine, Inc. (EDIT) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CADL carries a Unified Composite Score of 46.0/100 (HOLD) at $6.12 (43.5x Forward P/E, 0.0% operating margin), whereas EDIT carries 48.4/100 (HOLD) at $1.91 (N/M Forward P/E, -167.0% operating margin).

  • Composite vs. Pillar Nuance: While EDIT currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. CADL 46.0/100 HOLD), CADL captures the overall institutional head-to-head verdict (7–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -167.0% operating margin) and revenue trajectory (+0.0% vs. +37.4% YoY).
  • Technical & Structure Timing Caution: CADL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.7); meanwhile EDIT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CADL vs EDIT
CADL NASDAQ Head-to-Head Winner
Candel Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$6.12
-1.21% 1D
Market Cap $642.0M
TTM Revenue $31,000
Forward P/E 43.5x
Beta / 30D Vol 2.14β · 125% Vol
Unified Composite Score
46.0 / 100 HOLD
Tech 33.0 Fund 55.0 Flow 70.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -14.8%), weak momentum, RSI 31
RSI-14: 30.7 · SMA20: $8.33 · SMA50: $9.62
EDIT NASDAQ
Editas Medicine, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.91
-12.21% 1D
Market Cap $336.5M
TTM Revenue $50M
Forward P/E N/M
Beta / 30D Vol 2.32β · 102% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 33.0 Fund 55.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.3%), weak momentum, RSI 33
RSI-14: 33.4 · SMA20: $2.52 · SMA50: $2.61

6-Pillar Scorecard Institutional Category Breakdown (CADL 3 – 3 EDIT)

Columns: Metric · CADL · EDIT
1. Valuation Multiples CADL
Forward P/E 43.5x N/M
Trailing P/E 43.5x N/M
PEG Ratio N/M N/M
EV / Revenue N/M 5.2x
2. Growth & Scale EDIT
Revenue Growth (YoY) +0.0% +37.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $31,000 $50M
Market Cap $642.0M $336.5M
3. Profitability & Quality CADL
Gross Margin N/A -73.3%
Operating Margin 0.0% -167.0%
Net Profit Margin 0.0% -144.9%
Return on Equity (ROE) -93.7% -147.4%
4. Balance Sheet & Cash Flow CADL
Cash Generation (TTM) -$57M -$110M
Cash Flow Margin N/A N/A
Net Cash / Leverage $152M Net Cash $79M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EDIT
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 85.5% (18th %ile) 95.8% (38th %ile)
Put/Call OI Skew 0.50x (Call-Skewed) 0.29x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat EDIT
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Concentrated Oligopoly Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CADL (7) vs EDIT (3)
Institutional Metric CADL EDIT Criterion Row Edge
Market Capitalization
Scale
$642.0M $336.5M Larger Scale CADL
Trailing P/E Ratio
Valuation
43.5x N/M Lower Multiple CADL
Forward P/E Ratio
Valuation
43.5x N/M Lower Multiple CADL
Revenue Growth (YoY)
Growth
+0.0% +37.4% Higher Growth EDIT
Operating Margin (TTM)
Profitability
0.0% -167.0% Higher Margin CADL
Net Profit Margin
Profitability
0.0% -144.9% Higher Margin CADL
Return on Equity (ROE)
Capital Efficiency
-93.7% -147.4% Higher ROE CADL
52-Week Range Position
Momentum
18% ($4–$14) 11% ($2–$4) Stronger Trend CADL
Beta / 30D Volatility
Risk Regime
2.14β · 125% Vol 2.32β · 102% Vol Lower Realized Risk EDIT
Unified Institutional Score
Composite Signal
46.0 / 100 (HOLD) 48.4 / 100 (HOLD) Higher Composite EDIT
Trailing 12M Revenue (USD)
Operating Scale
$31,000 $50M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A -73.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 5.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$57M ($152M Net Cash) -$110M ($79M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EDIT +6.27 pp
CADL: -25.21% · EDIT: -18.94%
3M Horizon EDIT +15.32 pp
CADL: -49.17% · EDIT: -33.85%
6M Horizon CADL +2.23 pp
CADL: -22.47% · EDIT: -24.7%
1Y Horizon CADL +57.86 pp
CADL: +32.86% · EDIT: -25.0%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CADL Revenue EDIT Revenue CADL Op. Margin EDIT Op. Margin Margin Leader
FY2018 N/A $30M N/A -356.1% EDIT
FY2019 N/A $20M N/A -686.4% EDIT
FY2020 $0M $90M -11048.0% -148.6% EDIT
FY2021 $0M $30M -20580.8% -756.1% EDIT
FY2022 $0M $20M -27777.6% -1146.3% EDIT
FY2023 N/A $80M N/A -216.6% EDIT
FY2024 N/A $30M N/A -777.2% EDIT
FY2025 N/A $40M N/A -394.9% EDIT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CADL BREAKDOWN
98d in phase · OBV DISTRIBUTION
Current IV 85.5%
IV Percentile 18th %ile
Put/Call OI Skew 0.50x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact CADL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EDIT BREAKDOWN
146d in phase · OBV NEUTRAL
Current IV 95.8%
IV Percentile 38th %ile
Put/Call OI Skew 0.29x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EDIT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CADL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $642.0M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
EDIT Moat Profile Concentrated Oligopoly Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $336.5M market capitalization and -167.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published · CRISPR / Gene Editing

Investor FAQ CADL vs EDIT Key Questions & Quantitative Answers

As of Nov 16, 2026, Candel Therapeutics, Inc. (CADL) is the stronger overall head-to-head candidate over Editas Medicine, Inc. (EDIT) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CADL carries a Unified Composite Score of 46.0/100 (HOLD) at $6.12 (43.5x Forward P/E, 0.0% operating margin), whereas EDIT carries 48.4/100 (HOLD) at $1.91 (N/M Forward P/E, -167.0% operating margin). Composite vs. Pillar Nuance: While EDIT currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. CADL 46.0/100 HOLD), CADL captures the overall institutional head-to-head verdict (7–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -167.0% operating margin) and revenue trajectory (+0.0% vs. +37.4% YoY). Technical & Structure Timing Caution: CADL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.7); meanwhile EDIT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

EDIT leads the Growth & Scale pillar: CADL posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $31,000 TTM revenue (N/A gross margin, 0.0% operating margin), compared with EDIT at +37.4% YoY revenue growth and +0.0% YoY earnings growth on $50M TTM revenue (-73.3% gross margin, -167.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CADL cumulative revenue shifted N/A while EDIT shifted +33.3%. In operating R&D and SG&A reinvestment, CADL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EDIT.

CADL screens cheaper on headline valuation multiples. CADL trades at 43.5x Forward P/E, 43.5x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas EDIT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 5.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CADL (-93.7% ROE) versus EDIT (-147.4% ROE) capital efficiency.

In options market volatility and institutional positioning, CADL carries 85.5% implied volatility (18th %ile, Compressed (<25th %ile)), a 0.50x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.14β · 125% Vol realized risk). By comparison, EDIT carries 95.8% implied volatility (38th %ile, Balanced (25th–60th %ile)), a 0.29x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.32β · 102% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.